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Abstract
Despite the many advances in our understanding of the genetic basis of Mendelian forms of Parkinson’s disease (PD), a large
numberof early-onset cases still remain to be explained.Manyof these cases, presentwith a formof disease that is identical to that
underlined by genetic causes, but do not have mutations in any of the currently known disease-causing genes. Here, we
hypothesized that de novomutations may account for a proportion of these early-onset, sporadic cases. We performed exome
sequencing in full parent–child trios where the proband presents with typical PD to unequivocally identify de novomutations. This
approach allows us to test all genes in the genome in an unbiased manner. We have identiﬁed and conﬁrmed 20 coding de novo
mutations in 21 trios.Wehaveusedpublicly available population genetic data to compare variant frequencies andour independent
in-house dataset of exome sequencing in PD (with over 1200 cases) to identify additional variants in the same genes. Of the genes
identiﬁed to carry de novomutations, PTEN,VAPB andASNA1 are supportedby various sources of data to be involved in PD.We show
that these genes are reported to be within a protein–protein interaction network with PD genes and that they contain additional
rare, case-speciﬁc,mutations inour independent cohort of PD cases. Our results support the involvement of these three genes in PD
and suggest that testing for de novomutations in sporadic disease may aid in the identiﬁcation of novel disease-causing genes.
†The authors wish it to be known that, in their opinion, the ﬁrst two authors should be regarded as joint First Authors.
‡A complete list of the IPDGC members is listed in the Supplementary Material.
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Introduction
Although the detailed aetiology of Parkinson’s disease (PD)
remains largely unknown, data suggest the disease may be
triggered through different mechanisms: protein inclusions ac-
cumulation, diminished mitochondrial activity, proteasomal/
lysosomal dysfunction and impaired dopamine production (1).
An increasing numberof publications showa strong genetic com-
ponent for PD. Studies in familial forms of PD have allowed for
the identiﬁcation of disease-causing mutations in several
genes, causing either dominant or recessive forms of disease in-
heritance. Genome-wide association studies (GWAS) have also
signiﬁcantly contributed to a more comprehensive knowledge
of the risk loci involved in PD (2). Despite these results, there is
still a large number of sporadic, early-onset cases that carry no
mutation in the known PD genes. These individuals have, in
many cases, a form of disease that is indistinguishable from
genetically linked disease.
De novo mutations have been commonly studied in neurode-
velopmental disorders such as autism (3–5) and schizophrenia
(6,7) with only a few examples in neurodegenerative diseases.
De novo mutations in the ATP1A3 gene have been found as the
cause for rapid-onset dystonia parkinsonism (8), while Rosewich
et al. (9) reported de novo mutations in this gene in alternating
hemiplegia of childhood. De Carvalho Aguiar and colleagues
(10) showed one de novo mutation in TOR1A in a primary torsion
dystonia case. Two cases of static encephalopathy of childhood
with neurodegeneration in adulthood showed mutations in
WDR45 (11). In all these cases, patients start to show symptoms
during childhood or adolescence.
Recently studies have suggested the involvement of de novo
mutations in other neurodegenerative diseases, such as in
early-onset Alzheimer’s disease (AD) (12,13) and amyotrophic
lateral sclerosis (ALS) (14–17).
There is also preliminary evidence supporting the role of
de novomutations in PD: Puschmann and colleagues (18) reported
on a presumably de novo A53T mutation in SNCA and non-
mendelian multiplications of the gene (19,20) have also been
shown. More recently, Hansen and collaborators (21) described
two mutations in the SLC6A3 gene (encoding the dopamine
transporter, DAT1), one of which was presumed to be de novo. It
should be noted however that in both the SNCA A53T and the
SLC6A3 cases, the authors were not able to positively conﬁrm
the presence of de novomutations, given the absence of parental
DNA samples.
Here, we hypothesize that a subset of early-onset PD cases,
with no mutations in any of the known PD-causing genes, may
be due to the occurrence of de novo mutations. We used whole-
exome sequencing in full parent–child PD trios to unequivocally
identify these events.
Results
From the systematic analysis of the whole-exome sequencing
data, 24 genes showed de novo mutations in the trios. We vali-
dated 20 of the 24 variants with Sanger sequencing methods
(Table 1) comparing sequences from both parents with the pro-
band (examples for the three genes of interest in Fig. 1). The
four variants not validated were false positives from the exome
sequencing. We have identiﬁed, on average, one de novo coding
event per trio, which is in line with what would be expected for
the human population (22) (Table 2). Only four of the variants
identiﬁed have been previously described in population data-
bases: the variants in EPPK1, COL12A1, PEPD and SLC52A1 have
low frequencies ranging from 0.00003 to 0.003 in Exome Aggrega-
tion Consortium (ExAC). All other variants are presumably novel
as they are absent from tested databases. PD cases did not show
any potential pathogenic mutations in the known PD genes—all
variants identiﬁed in those geneswere either frequent in the gen-
eral population, present in the unaffected parents, located in not
conserved residues or predicted to be benign by PolyPhen and
SIFT (23,24).
From the protein network analysis of the 20 validated de novo
mutation carrying genes, PTEN, VAPB, ASNA1, PML and VPS53
showed interactions with the known PD genes (Fig. 2). However,
VPS53 and PML did not show high interaction scores with dis-
ease-causing genes. Robust functional interactions with known
PD genes were identiﬁed for the three remaining candidates.
(Table 3 and Fig. 2).
A total of 10 interactions were observed between proteins cor-
responding to genes containing de novo variants and proteins cor-
responding to known PD genes. This is signiﬁcantly higher than
expected by chance (P = 0.009), however, after correcting for the
total numbers of interactions observed for each protein, the re-
sult does not retain statistical signiﬁcance (P = 0.162). Five out of
the ten interactions involved PTEN. Nevertheless, this number
was not signiﬁcantly higher than expected by chance (P = 0.226),
after correcting for the large total number of interactions involv-
ing PTEN.
Seventy-four interactions were observed between the proteins
corresponding to the 33 known PD genes. This is signiﬁcantly
higher than expected by chance (P < 0.000001). Several individual
proteins showed a signiﬁcant excess of interactions, even after
correcting for themultiple testing of proteins. The interaction net-
work between the proteins corresponding to PD genes is shown in
Supplementary Material (see Supplementary Material, Table S1
and Fig. S1).
Interestingly, when taking into account the allele frequency
from the ExAC database for all the genes studied here, we ob-
served the lowest total number of variants normalized by protein
size to be present in the three genes with higher interaction with
known PD genes—PTEN, VAPB and ASNA1 (see Supplementary
Material, Fig. S2), suggesting these may be under stronger selec-
tion pressure.
The International Parkinson’s Disease Genomics Consortium
(IPDGC) dataset shows 2missense and 1 frameshift mutations in
PTEN (all in PD cases, no rare variants were found in controls); 4
missense, 1 frameshift and 1 stop-gained mutations in ASNA1;
and 5 missense and 1 deletion mutations in VAPB. With the ex-
ception of three common variants in VAPB, all others are exceed-
ingly rare in the population (Table 4) and heterozygous in the
IPDGC dataset.
The frameshift mutation in PTEN (NM_000314:c.955_958de-
lACTT:p.Thr319*) was identiﬁed in a case from the IPDGC dataset
with positive, albeit limited, family history for PD: the proband’s
father developed the disease in his 50s. Samples from both par-
ents andunaffected siblingwere available. After testing for segre-
gation in the limited family, we observed that the mutation in
PTEN is, in all likelihood, de novo, since it is absent from either
parent, and thus unlikely to cause the disease in this family.
However, we should note that the age at onset is noticeably dif-
ferent between the affected father and the proband in this family
(54 years in the father and 38 years in the proband).
When looking at the cases with conﬁrmed de novo mutations
in the geneswith a functional interactionwith known PD causing
genes, these showed a typical presentation of PD.
The PTEN de novo mutation carrier, aged 23, is a British
Caucasian male who noticed a left-sided thumb action tremor.
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Table 1. List of de novo variants identiﬁed in the PD trios
Trio Gene Chromosome Position Transcript Codon
change
Amino
acid
change
Reference
SNP
SIFT
prediction
Polyphen
prediction
CADD
phred
score
ESP6500 1000
Genomes
ExAC
1 COL12A1 6 75 887 555 NM_004370 cGa/cAa R754Q rs377480187 None Probably_Damaging 32 0.000084 0 0.00003311
RUNDC3A 17 42 390 571 NM_001144825 tGt/tTt C108F Deleterious Probably_Damaging 22.2 0 0 0
VAPB 20 56 9932 80 NM_004738 gaTGTt/
gat
ΔV25 None None None 0 0 0
2 ANKRD13A 12 1 104 655 60 NM_033121 Ggt/Tgt G312C Deleterious Possibly_Damaging 22.8 0 0 0
MKS1 17 56 293 486 NM_001165927 aCc/aTc T117I Deleterious Probably_Damaging 33 0 0 0
3 PAPD4 5 78 938 703 NM_173797 Tta/Gta L241V Tolerated Benign 15.53 0 0 0
VPS53 17 455 114 NM_001128159 Aag/Gag K622E Deleterious Probably_Damaging 29.7 0 0 0
4 PMEL 12 56 349 087 NM_001200054 atG/atA M614I Tolerated Benign 10.33 0 0 0
SLC5A9 1 48 695 007 NM_001135181 cCt/cTt P152L Deleterious Probably_Damaging 33 0 0 0
5 ASNA1 19 12 858 398 NM_004317 Ctg/Gtg L303V Deleterious Benign None 0 0 0
6 EPPK1 8 14 494 1903 NM_031308 aCg/aTg T1840M rs79961029 Tolerated Benign 9.541 0.008705 0.00838658 0.003023
7 FBXL17 5 10 770 3586 NM_001163315 gaC/gaA D354E Tolerated Possibly_Damaging 17.45 0 0 0
8 KCNV2 9 27 189 66 NM_133497 caG/caT Q409H Tolerated Benign 13.86 0 0 0
9 LCT 2 13 654 8243 NM_002299 Aat/Cat N1774H Deleterious Probably_Damaging 21.9 0 0 0
10 MGA 15 41 988 608 NM_001164273 cCa/cAa P467Q Deleterious Probably_Damaging 16.87 0 0 0
11 PEPD 19 33 878 830 NM_000285 cGc/cAc R437H rs373297406 Tolerated Benign 13.91 0.000329 0.000199681 0.00006709
12 PML 15 74 327 974 NM_033250 cgG/cgC R676R None None None 0 0 0
13 PSD4 2 11 395 0082 NM_012455 aAc/aGc N585S Tolerated Benign 9.504 0 0 0
14 PTEN 10 89 711 992 NM_000314 Cca/Tca P204S Tolerated Possibly_Damaging 32 0 0 0
15 SLC52A1 17 49 363 59 NM_001104577 Gcc/Acc A414T rs142353672 Tolerated Benign 11.56 0.007 0 0.00005776
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Gradually, the tremor progressed to be present at rest and to in-
volve his left arm. Four years later, he developed gait difﬁculties
with some shufﬂing and stumbling. During the same period the
tremor spread to involve his right arm aswell, and at the age of 28
he was diagnosed with young-onset Parkinson’s disease (YOPD).
He was started on carbidopa/levodopa with signiﬁcant improve-
ment on his gait but no effect on the tremor. Only two years after
treatment, he developed drug-induced dyskinesias. At the time
his treatment had consisted of carbidopa/levodopa, rasagiline
and ropinirole, and, thus, amantadine was added. Age 32 and
due to clinical progression and particularly more severe dyskine-
sias, the patient underwent bilateral deep brain stimulation of
the subthalamic nucleus with very good response. Currently, at
the age of 36, he suffers from off-periods, has difﬁculties speak-
ing, aswell as increased urinary urgency. Hismedication consists
of carbidopa/levodopa, entacapone, rasagiline, ropinirole and
amantadine.
TheVAPB de novomutation carrier is a 44-year-old Caucasian
man of British descent, who ﬁrst noticed a left arm rest tremor
at the age of 41. He also complained of shoulder stiffness on the
same side and some difﬁculties in performing ﬁne tasks with
his left hand. Clinical examination revealed asymmetric par-
kinsonism (left>right side) and a subsequent dopamine trans-
porter SPECT scan (DaTSCAN) conﬁrmed the presence of a
presynaptic dopaminergic deﬁcit corresponding to the more
affected body side. He was diagnosed with YOPD. Treatment
was commenced with rasagiline and subsequently pramipex-
ole was added.
The ASNA1 de novomutation carrier developed PD at an age of
40 years. The ﬁrst symptom was reduced right arm swing, soon
followed by tremor, muscle stiffness, dexterity, gait and writing
difﬁculties. At age 43 he experienced fatigue, constipation and
freezing. The father is healthy and the mother suffers from
rheumatoid arthritis. The family history for PD is negative.
Figure 1. Sanger sequencing chromatograms for (A) ASNA1 (p.L303V); (B) PTEN
(p.P204S); and (C) VAPB (p.ΔV25). Top: father; middle: mother; bottom: proband.
Table 2. Sequencing metrics
Proband Total on
target (bp)
Mean on
target
coverage
Fraction
targeted
bases >2x
Total de novo
coding
mutations
1 1 445 598 290 27.12 0.97 3
2 1 421 276 651 26.52 0.97 2
3 1 146 375 416 21.47 0.97 2
4 7 152 790 854 135.14 0.94 2
5 8 974 607 696 167.43 0.94 1
6 7 933 070 487 147.95 0.94 1
7 1 376 003 145 26.44 0.97 1
8 1 914 732 654 36.21 0.98 1
9 4 286 967 024 76.61 0.95 1
10 6 133 197 922 112.73 0.97 1
11 3 381 480 354 61.73 0.94 1
12 6 529 240 671 121.95 0.94 1
13 4 485 511 060 87.10 0.99 1
14 1 843 089 171 33.41 0.98 1
15 6 364 816 268 119.29 0.94 1
16 3 347 839 519 59.15 0.95 0
17 1 171 269 433 22.19 0.96 0
18 2 110 891 218 39.22 0.98 0
19 4 145 185 493 80.55 0.99 0
20 3 649 693 000 70.18 0.99 0
21 1 461 050 157 28.87 0.93 0
Average 3 822 604 118 71.49 0.96 0.95
6714 | Human Molecular Genetics, 2015, Vol. 24, No. 23
Discussion
This is the ﬁrst study to systematically screen for de novo muta-
tions in early-onset sporadic PD using parent–proband trios. We
performed exome sequencing in 21 trios and found 20 de novo
mutations (19 single nucleotide variants and one in-frame dele-
tion). All probands were heterozygous in those positions. The
genes screened are involved in a variety of functions from poly
(A) polymerase activity to ubiquitin-binding protein (see Supple-
mentary Material, Table S2) and some are thought to be involved
in known PD pathways.
PTEN, the phosphatase and tensin gene, has functions
in neuronal migration, neuron number regulation and apop-
tosis in response to oxidative stress (25). PTEN somatic down-
regulation has been linked to tumours, neural proliferation and
is being proposed as a target for neuroprotection in PD cases
(26,27), whereas PTEN mutations in the germline have been
linked to developmental neurological diseases (28). Mutations
in PTEN are mainly linked to macrocephaly, autism and ataxia
(29–32).
We found novel variants in PTEN. One of our trio-based pro-
band showed a de novo missense mutation in PTEN (p.P204S).
Interestingly, mutations in PTEN seem to be rare: there is only
one stop-gained and one frameshift in ExAC for a total of 149
coding variant alleles out of ∼120 000. Similarly, in our IPDGC da-
taset we found a relatively small number of variants in PTEN:
four synonymous mutations, two missense mutations (p.N69D
and p.N117S) and one frameshift, all of them very rare or non-
existent in the population (Table 4). The twomissensemutations
are from patients with sporadic PD and the patient with the
Figure 2.Action view from the STRING network analysis. Colours correspond to interactions according to the legend (top left); Evidence view (grey) correspondsmainly to
interactions obtained from text-mining sources. The remaining interaction colours are based on published experimental results, with Green representing activation, Red
inhibition, etc. If the directionality of the effect is known, this is indicated by the symbol at the end of the edge next to the protein that is acted upon. Down-regulation is a
red bar and up-regulation is a green arrow. *denotes genes identiﬁed to carry de novomutations.
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frameshift mutation has a reported positive familial history of
PD. Although the frameshift mutation did not show segregation
in this family, it is remarkable that it is another apparent de novo
mutation in a case with a much lower age at onset than the af-
fected father.
The delicate equilibrium of the various functions of PTEN
means that it is often difﬁcult to interpret genetic variability in
this gene. PTEN transcriptionally activates PINK1, which is down-
regulated in the event of PTEN ablation (33,34). PINK1 variants are
responsible for PD through a mechanism that is thought to in-
volve oxidative stress caused by mitochondrial dysfunction.
PTENwas also linked to the induction of cytochrome c oxidase ac-
tivity and ATP production in mitochondria (34). On the other
hand, PTEN induces cell death and inhibits the PI3K/Akt signal-
ling that reduces inﬂammation and promotes cell proliferation
and survival (26). Furthermore, DJ-1 physically binds to PTEN
negatively regulating its activity which, in turn, upregulates
PI3K/Akt pathway (35).
PTEN has a large range of activities and cellular locations in a
variety of cells. Different mutations in this gene can affect PTEN
activity and localization in different ways (36). Deletion of the
N-terminal domain PBM (residues 1–15) impedes PTEN inter-
action with the plasma membrane [see (37) for PTEN protein
structure]. When the phosphatase domain (residues 15–185) is
mutated, there is a reduction in phosphatase activity and an
increase in PI3K/Akt activity. The C2 domain (residues 185–351)
inhibits cell migration. The C-tail domain (residues 351–401) is
important for interactions with transmembrane proteins and a
2 bp C-terminal PDZ-binding domain (36).
Most of the mutations described for developmental anomal-
ies are missense mutations and appear mainly on the phosphat-
ase and C2 domains, e.g. (30,32,38,39). In addition, a variant can
Table 3. Scores from the STRING protein–protein analysis restricted to Homo sapiens
Gene Interaction Total score Co-expression Experimental Knowledge Text-mining
PTEN PARK7 0.990 0 0.844 0 0.940
SYNJ1 0.928 0 0.116 0.900 0.242
PINK1 0.699 0 0.172 0 0.643
LRRK2 0.667 0 0.295 0 0.537
PARK2 0.608 0 0 0 0.599
SNCA 0.472 0 0 0 0.472
VAPB STX1B 0.919 0 0.730 0 0.697
SYNJ1 0.510 0 0.363 0 0.245
VPS13C 0.449 0 0 0 0.436
PML HLA-DRB5 0.900 0 0 0.900 0
PARK2 0.507 0 0 0 0.507
ASNA1 VAPB 0.887 0 0.413 0 0.812
VPS53 VPS35 0.502 0.111 0 0 0.451
LRRK2 0.413 0 0.102 0 0.374
The total scores are computed by combining the probabilities from the different evidence channels (co-expression, experimental, knowledge, text-mining), correcting
for the probability of randomly observing an interaction, as described in STRING′s documentation.
Table 4. List of IPDGC variants in the top candidate genes
Gene Chromosome Position rs_ids Codon change Amino acid
change
MAF
cases
MAF
controls
MAF
ESP6500
MAF ExAC ExAC
alleles
ASNA1 19 12 848 341 Frameshift
(insG)
−8 0.039 0 0 0 0
12 848 341 Tgg/Ggg W8G 0.039 0 0 0 0
12 848 342 rs138730527 tGg/tAg W8* (stop
gained)
0 0.099 0.0154 0.00001726 1
12 849 344 Ctc/Gtc L61V 0.039 0 0 0 0
12 849 356 Cgt/Tgt R65C 0.039 0 0 0 0
12 858 023 Ctg/Gtg L208V 0.039 0 0 0 0
12 858 901 rs200489378 Ccc/Tcc P344S 0.039 0 0.0077 0.00007819 9
PTEN 10 89 685 310 Aat/Gat N69D 0.04 0 0 0 0
89 692 866 aAt/aGt N117S 0.039 0 0 0.000008237 1
89 720 798 Frameshift
(delTACT)
−317 0.039 0 0 0 0
VAPB 20 56 964 571 cGa/cTa R19L 0.041 0 0 0 0
57 014 058 Ttg/Atg L125M 0.039 0 0 0.00001661 2
57 014 075 rs146459055 gaT/gaG D130E 0.079 0 0.0692 0.001359 163
57 016 039 agttct/agt (del) SS160S 0.313 0.298 0 0.001695 203
57 016 076 rs143144050 atG/atA M170I 0.313 0.099 0.1153 0.001373 165
57 016 117 rs145483046 cGg/cAg R184Q 0.039 0 0.0308 0.00007541 9
Synonymous mutations were not included.
MAF, minor allele frequency.
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affect the gene’s function only in speciﬁc subcellular localiza-
tions. In 2007 Trotman and colleagues (40) described a missense
mutation p.K289E that did not affect the membrane localization
of PTEN, but the protein was not present in the nucleus. Another
nuclear mislocalization was apparent whenmutations were pre-
sent in the ATP binding motifs at the residues 60–73 and 122–136
(41). This nuclear mislocalization was observed in AD cases with
the redistribution of PTEN to the cytoplasm into intracellular
neuroﬁbrillary tangles and senile plaques (42).
VAPB is involved in vesicular and endosomal trafﬁcking and
was identiﬁed in ALS cases (43–45). VAPB expression levels are
signiﬁcantly lower in the spinal cord of ALS cases (46). Further-
more, missense mutations in VAPB protein such as p.P56S
and p.T46I cause intracellular ubiquitinated aggregates that pre-
dominantly affect motor neurons and induce motor neuron
death (43,45).
We found a de novo in-frame deletion of a valine residue at
position 25 (p.ΔV25) in VAPB. Only one other deletion in VAPB
was documented, p.ΔS160, which is common in the population
and any association with ALS was discarded (47). Interestingly,
there are only two high impact variants in VAPB in the ExAC da-
taset: two nonsense variants each in a single sample, out of
>60 000 individuals.
Structural studies indicate human VAPB protein is organized
in three main conserved domains consisting of the N-terminal
major sperm protein (MSP) domain from residue 1 to 125, the
coiled coil (CC) domain from residue 151 to 195 and the C-termin-
al transmembrane (TM) domain including the remaining resi-
dues until residue 243 (48). The MSP is very important in VAPB
as it is the domain that binds to the FFAT (two phenylalanines
in an acidic tract) motif of lipid-binding-proteins and is involved
in the ubiquitination pathway. VAPB binds through that domain
to proteins such as STX1A and STX1B, p97 ATPase and ASNA1
(49). Misfolding of MSP domain induces the formation of the ag-
gregates and the binding site becomes unavailable on the endo-
plasmic reticulum (50).
As Gupta et al. (48) noticed, the p.T46I and p.P56S missense
mutations that cause ALS are located in the MSP. On the other
hand, the p.ΔS160 deletion, located on the CC is common and
does not cause ALS. Additionally, another study detected a mis-
sense variant p.D130E that showed no prevalence in cases (51)
and falls between the MSP and the CC domains. Mutations in
the MSP could be the leading cause for the dysfunction in the
motor neurons. Nevertheless, some evidence in Drosophila is
starting to show that mutations in the C-terminal TM can
cause neurodegeneration in the corresponding variant p.V234I
in humans (52).
Our results follow the same trend. The identiﬁed de novo
p.ΔV25 deletion is absent in the general population and is located
in the MSP. The mutations p.R19L and p.L125 M identiﬁed in the
IPDGC dataset, both from sporadic cases, are also in the MSP
(Table 4), are not present in the general population and only the
latter shows two heterozygous cases in ExAC. When moving
towards the CC in the IPDGC dataset, we ﬁnd the frequent
p.D130E and p.ΔS160 variants mentioned above, and two extra
missense mutations (p.M170I and p.R184Q) with higher frequen-
cies in the general population.
We found theVAPB de novovariant in a triowith two additional
de novo variants in COL12A1 (p.R754Q) and RUNDC3A (p.C108F).
COL12A1was associated withmyopathy (53) and the only associ-
ation to a neurodegenerative disease is its decreased amount in
the cervical spinal cord of patients with ALS (54). COL12A1 pre-
sented 96 variants in the IPDGC dataset (see Supplementary Ma-
terial, Table S3). In contrast, RUNDC3A presented ﬁve mutations,
three of them rare and observed only in patients. Due to the fact
that this trio presented three conﬁrmed de novo variants, it is not
possible to say with certainty, which, if any, is associated with
the disease. However the fact that VAPB directly interacts with
known PD genes strongly argues in favour of the involvement
of this gene.
The results atVAPB and PTEN, which have both been shown to
be involved in disparate phenotypes, ﬁt nicely with the growing
body of evidence suggesting that pleiotropic events are a greatly
underappreciated event in human disease (55).
For ASNA1, we found one de novomissense mutation p.L303V
in one of the trios not present in any database. High impact
variants in this gene seem rare, with mainly missense variants
present in ExAC and only three frameshifts (1 allele each)
and one stop-gainmutations. In the IPDGCdataset,we see a simi-
lar trend with only seven rare variants. The missense variants in
IPDGC (Table 4) were identiﬁed in patients presenting with posi-
tive familial history of PD (variants: p.L61V and p.R65C); and
early-onset sporadic PD (variant p.L208V). ASNA1 is known to
have a function in transporting proteins as a part of the trans-
membrane recognition complex (TRC). Interestingly, ASNA1 has
been shown to bind to VAPB (49), although a role in human
neurodegenerative diseases has still to be investigated.
In conclusion, we have identiﬁed de novo mutations in
early-onset, sporadic PD cases. We have used publicly available
population genetic data and our in-house dataset of exome-
sequenced PD cases and controls to replicate and conﬁrm our
ﬁndings. From our list of conﬁrmed de novo mutations, three
genes are particularly interesting, as they have been reported to
interact with known PD genes and present rare, case-speciﬁc
variants in our large cohort of PD cases.
It is plausible that some of the apparently sporadic PD cases
are due to recessive or compound heterozygous mutations in
genes yet to be associatedwith disease; howeverwe did not iden-
tify any better recessive candidates in these trios.
The present study has some shortcomings that we are not
able to immediately address. The sample size is small; unfortu-
nately it is very difﬁcult to identify PD cases with both parents
available for genetic analyses. The methodology used, although
appropriate and in line with what has been previously published
for de novo mutations in disease, misses a signiﬁcant amount of
genetic variability, particularly in the form of non-coding
variants. Additionally, apparently de novo variants can actually
be inherited from a parent that has low-level mosaicism for
that variant. This is a difﬁcult issue to address [as recently
shown by Acuna-Hidalgo and colleagues (56)] and would require
very high sequencing coverage, perhaps even ofmultiple tissues,
in all individuals and is thus beyond the scope of the present
work. In addition, deﬁnitive proof of pathological signiﬁcance
for PD can only be achieved by one of the following: identifying
the same mutation in complete segregation in large families,
identifying multiple families with even limited segregation of
the same variants or functional studies of the protein harbouring
the mutations showing altered function.
On the other hand, we have been able to screen, in an un-
biased manner, a cohort of over 1200 PD cases and 400 controls
for mutations in all of the genes identiﬁed in our trio study,
having conﬁrmed the presence of rare, case-speciﬁc mutations
in the same genes.
De novomutations may be a vastly underappreciated cause of
apparently sporadic forms of adult-onset disease, such as PD.We
show de novo mutations in genes, which are known to interact
with known PD-causing genes, and we suggest these may be
responsible for the disease in these cases.
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Material and Methods
We performed whole-exome sequencing in 21 full trios. Criteria
for inclusion of cases were based on age at onset (<40 years), typ-
ical presentation of PD with negative family history, absence of
pathogenic mutations in any of the known PD genes and avail-
ability of both parents for genetic studies. All cases included are
of European descent.
Exomes for the 21 trios were captured using Illumina’s Nex-
tera Rapid Capture according to the manufacturer’s recommen-
dations. Indexed and pooled libraries were then sequenced on
Illumina’s HiSeq2000 (100 bp, paired-end) to amean target cover-
age of 30×. Reads were mapped to GRCh37 using bwa-mem
(0.7.12) and followed GATK Best Practices for v3 (57). Brieﬂy, this
consisted of ﬂagging duplicate reads, realignment around indels,
base recalibration and variant calling on all trios simultaneously
using the HaplotypeCaller tool. Variant qualities were then reca-
librated as described in DePristo et al. (58). After obtaining a
high quality variant set, we performed a genotype-reﬁnement
protocol, as described in (http://gatkforums.broadinstitute.org/
discussion/4723/genotype-reﬁnement-workﬂow). This protocol
uses population and pedigree priors to improve estimates of
genotype likelihoods, providing higher quality variant calls.
To conﬁrm all relationships and identify unreported familial
relationships, we performed identity-by-descent (IBD) estimation
for all pairs of individuals. The proportion of IBD was obtained
with PLINK (59) and varied between 0.35–0.45 for the trio pairs of
each parent with the descendant, and equal to zero between par-
ents and all the remaining pairs. The lower end of the spectrum of
IBD values is due to lower variant qualities in some samples.
We used three publicly available resources to extract genome-
wide variant frequency data: the Exome Sequencing Project
(ESP6500) (60), the 1000 Genomes Project (Oct 2014) (61) and the
ExAC (62).
Sanger sequencing was used to conﬁrm the presence of all
de novo mutations identiﬁed by whole-exome sequencing.
Primers designed for this validation are shown in the Supple-
mentary Material (see Supplementary Material, Table S4; PCR
conditions used are available upon request). Table 1 shows
each of the transcripts used as basis for annotation of the
variants identiﬁed.
Protein–protein interactions and functional protein associa-
tions were deﬁned with STRING v10 (63). The input consisted of a
list of known PD genes (64), and genes containing validated de novo
variants. We considered total scores above 0.400 (medium conﬁ-
dence) that correspond to the combination of four different scores:
co-expression, experimental, knowledge and text-mining. The
total number of interactions between proteins corresponding to
genes containing de novo variants and proteins corresponding to
known PD genes was calculated, as was the number of such inter-
actions involving the protein corresponding to de novo gene in turn.
The signiﬁcance of these quantities was assessed by randomly po-
sitioning the proteins corresponding to de novo and known PD
genes on the interaction map such that each protein is mapped
to a protein with the same total number of interactions (to avoid
potential bias causedby the genes of interest having largenumbers
of interactions, thus being likely to interact with each other by
chance). The number of interactions between each de novo protein
and PD proteins, and the total number of such interactions, was
calculated on the randomized map and compared with that ob-
served in the actual data. This process was repeated 1 000 000
times to obtain P-values. Correction formultiple testing of proteins
was performed by comparing the maximum number of interac-
tions for any single protein in each simulated dataset to the
number of interactions observed for each protein in the real data.
A similar procedure was used to test for an excess of interactions
between the proteins corresponding to known PD genes. It should
be noted that throughout the text, interactions are deﬁned as per
STRING’s deﬁnitions and in many cases these are only predicted,
without experimental evidence.
Finally, we extracted information for genes of interest from
in-house data, produced within the IPDGC. This dataset con-
sisted of a total of 1715 samples exome-sequenced with 1243 of
diagnosed PD cases and 472 controls. Details from this dataset
have been previously published (65).
Supplementary Material
Supplementary Material is available at HMG online.
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